These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
954 related articles for article (PubMed ID: 36048514)
1. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines. Li WH; Su JY; Li YM Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514 [TBL] [Abstract][Full Text] [Related]
2. Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy. Song H; Su Q; Nie Y; Zhang C; Huang P; Shi S; Liu Q; Wang W Acta Biomater; 2023 Mar; 158():535-546. PubMed ID: 36632876 [TBL] [Abstract][Full Text] [Related]
4. Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles. Yan H; Lin G; Liu Z; Gu F; Zhang Y Acta Biomater; 2023 Apr; 161():213-225. PubMed ID: 36858163 [TBL] [Abstract][Full Text] [Related]
5. MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses. Taylor D; Meyer CT; Graves D; Sen R; Fu J; Tran E; Mirza B; Rodriguez G; Lang C; Feng H; Quaranta V; Wilson JT; Kim YJ; Korrer MJ Front Immunol; 2022; 13():936129. PubMed ID: 36059502 [TBL] [Abstract][Full Text] [Related]
6. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists. Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282 [TBL] [Abstract][Full Text] [Related]
7. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy. Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785 [TBL] [Abstract][Full Text] [Related]
8. Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy. Su T; Cheng F; Qi J; Zhang Y; Zhou S; Mei L; Fu S; Zhang F; Lin S; Zhu G Adv Sci (Weinh); 2022 Aug; 9(23):e2201895. PubMed ID: 35712773 [TBL] [Abstract][Full Text] [Related]
9. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Ruffini PA; Neelapu SS; Kwak LW; Biragyn A Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812 [TBL] [Abstract][Full Text] [Related]
10. Albumin and interferon-β fusion protein serves as an effective vaccine adjuvant to enhance antigen-specific CD8+ T cell-mediated antitumor immunity. Tseng SH; Cheng MA; Farmer E; Ferrall L; Kung YJ; Lam B; Lim L; Wu TC; Hung CF J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35459734 [TBL] [Abstract][Full Text] [Related]
11. CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 1 helper CD4+ and central memory CD8+ T cell responses. Umeshappa CS; Huang H; Xie Y; Wei Y; Mulligan SJ; Deng Y; Xiang J J Immunol; 2009 Jan; 182(1):193-206. PubMed ID: 19109150 [TBL] [Abstract][Full Text] [Related]
12. Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity. Brown M Cancer Treat Res; 2022; 183():91-129. PubMed ID: 35551657 [TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor agonists as cancer vaccine adjuvants. Jeon D; Hill E; McNeel DG Hum Vaccin Immunother; 2024 Dec; 20(1):2297453. PubMed ID: 38155525 [TBL] [Abstract][Full Text] [Related]
14. Orchestrated Codelivery of Peptide Antigen and Adjuvant to Antigen-Presenting Cells by Using an Engineered Chimeric Peptide Enhances Antitumor T-Cell Immunity. Pan H; Yu S; Zhuang H; Yang H; Jiang J; Yang H; Ren S; Luo G; Yu X; Chen S; Lin Y; Sheng R; Zhang S; Yuan Q; Huang C; Zhang T; Li T; Ge S; Zhang J; Xia N Cancer Immunol Res; 2024 Jul; 12(7):905-920. PubMed ID: 38631019 [TBL] [Abstract][Full Text] [Related]
15. DNA vaccine for cancer immunotherapy. Yang B; Jeang J; Yang A; Wu TC; Hung CF Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927 [TBL] [Abstract][Full Text] [Related]
17. Antigen-specific vaccines for cancer treatment. Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639 [TBL] [Abstract][Full Text] [Related]
18. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses. Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004 [TBL] [Abstract][Full Text] [Related]
19. Approaches to Improve Chemically Defined Synthetic Peptide Vaccines. Hos BJ; Tondini E; van Kasteren SI; Ossendorp F Front Immunol; 2018; 9():884. PubMed ID: 29755468 [TBL] [Abstract][Full Text] [Related]